3 Houston innovators to know this week

who's who

This week's roundup of Houston innovators includes Reginald DesRoches of Rice University, Tatiana Fofanova of Koda Health, and Arun Swaminathan of Coya Therapeutics. Photos courtesy

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes three innovators across academia and health care innovation.

Reginald DesRoches, president of Rice University

Rice University President Reginald DesRoches joins the Houston Innovators Podcast to discuss balancing tradition with growth, innovation, and global impact in education. Photo courtesy Tommy LaVergne/Rice University

How does a historic university maintain its legacy while still making room for growth and increased opportunities? That's what Rice University President Reginald DesRoches considers with every decision he makes.

"It's this idea of preserving what's special about the university, while also knowing we need to adapt to a new time, a new Rice, a new time in higher ed, and a new time in society," DesRoches says on the Houston Innovators Podcast.

"There's a healthy tension between preserving what Rice is known for — the culture of care, the close-knit community — while knowing that we need to grow, have a global impact, and position Rice on a global scale. It's something that's constantly in my mind to make sure we do both." Continue reading.

Tatiana Fofanova, CEO of Koda Health

Koda Health has a new service for the 37 million Americans living with Chronic Kidney Disease. Photo courtesy of Koda Health

Chronic Kidney Disease is expensive and common. In fact, 37 million Americans live with the condition. The winner of this year’s Houston Innovation Award for best female-founded business, Koda Health, recognized the need for help among CKD sufferers and has answered the call.

Last week, Koda Health announced the addition of Kidney Action Planning to its suite of services for patients with serious illnesses.

"Kidney Action Planning is designed to fill a significant void in CKD management," Tatiana Fofanova, CEO of Koda Health, says in a statement. "Some studies indicate greater than 70 percent of patients start dialysis in the ER suboptimally, potentially navigating a life-or-death scenario. This is both frightening and largely avoidable with an intervention like Kidney Action Planning, which helps patients better understand CKD.” Continue reading.

Arun Swaminathan, CEO of Coya Therapeutics

Coya Therapeutics appoints a new CEO to lead its innovative Alzheimer's treatment development efforts. Photo via LinkedIn

Coya Therapeutics has named a new CEO. As of Nov. 1, Arun Swaminathan replaced Co-founder Howard Berman in the role. Berman has assumed the title of executive chairman, in which he will still remain active with the company.

Swaminathan started with Coya two years ago as chief business officer. This transition was planned, says the PhD-holding scientist and businessman.

Coya Therapeutics is a publicly traded biotechnology company that is working on two novel treatments for Alzheimer's disease. Coya's therapeutics, which are currently in trials, use regulatory T cells (T regs) to target both systemic- and neuroinflammation in patients. Continue reading.

Coya Therapeutics appoints a new CEO to lead its innovative Alzheimer's treatment development efforts. Photo via LinkedIn

New CEO brings strategic vision to Houston co. advancing neurodegenerative disease treatments

Q&A

Coya Therapeutics has named a new CEO. As of Nov. 1, Arun Swaminathan replaced Co-founder Howard Berman in the role. Berman has assumed the title of executive chairman, in which he will still remain active with the company.

Swaminathan started with Coya two years ago as chief business officer. This transition was planned, says the PhD-holding scientist and businessman.

“(Berman's) intent was that it was the right time to put in place a CEO that, as we move into the operational phases of the company, that can take the reins from him,” he tells InnovationMap.

Coya Therapeutics is a publicly traded biotechnology company that is working on two novel treatments for Alzheimer's disease. Coya's therapeutics, which are currently in trials, use regulatory T cells (T regs) to target both systemic- and neuroinflammation in patients.

InnovationMap: Berman has been a very visible CEO. Will you follow suit?

Arun Swaminathan: I think it's part of the CEO’s job to be visible and to communicate the value of our company to all the stakeholders out there. So yes, I do plan to be visible as well. Obviously, Howard as the founder had elements that he talked about, the foundational stories. I obviously will be doing less of that.

IM: What was your journey from the lab to the boardroom?

AS: I have a PhD from the University of Pittsburgh. I like to say that I grew up at Bristol Myers Squibb, so I started in a clinical pharmacology group at BMS, running clinical trials, but in the cardiovascular and metabolic space.

What happened was, as I was the study director on a diabetes trial there, and the data starts coming in for these early diabetic trials, and I got highly involved with the commercial folks at BMS in starting to plan out “What does the target profile look like? How is this going to play out in the real world?” You know, the marketing teams and commercial teams start engaging when clinical data is available, because they're starting to plan for the eventual launch of the product.

That gave me a lot of exposure to the commercial side of things, and I also got a lot of experience presenting to opinion leaders and others through that role. And I said, “What I really love is that intersection between science and business.” And so I think that was my moment.

Then I moved to business development and licensing, where I helped scan the universe for assets and talk to CEOs of companies like Coya as a junior person, trying to understand if there's something that we can bring into BMS to strengthen the pipeline of BMS. So that gave me exposure to deals, how deals are structured, how you negotiate a lot of that kind of stuff.

Then I said, “Look, if I want to be a complete person in biotech, I do need to go into more true commercial roles.” So I went into commercial strategy. I was involved in the commercial strategy for what is now known as Eliquis. Was back then known as apixaban. That’s still the generic name.

Then I led marketing for Orencia, a rheumatoid arthritis drug. So I went and got both strategic and tactical marketing experience at BMS, and then I used all of that experience, rounded up. I eventually ended up co-founding a company, and that's led me to the last nine years with smaller biotech companies. So that's my evolution and path. But I think my true moment of realization was about three years into my clinical role at BMS, when I said, what I really enjoy is translating good science into commercial value, and I think that's what excites me.

IM: Why is Houston an important part of Coya's success?

AS: It is important that Coya stays in Houston, because we have a very close association with Houston Methodist, we get a lot of our work, our early research work still done through Houston Methodist, through Dr. [Stanley] Appel's lab and through other experts. We absolutely have a special research agreement with Houston Methodist, so we have a very strong reason to be in Houston. So, we do not anticipate moving out of Houston.

------

This conversation has been edited for brevity and clarity.

These five scaleups stood out to the judges of the 2024 Houston Innovation Awards. Photo via Getty Images

Meet 5 of the fastest-growing scaleup companies in Houston

houston innovation awards

The 2024 Houston Innovation Awards will feature a new category: Scaleup of the Year, which honors a Bayou City company that's seen impressive growth in 2024.

From biotech companies to decarbonization startups, the inaugural finalists have expanded internationally, moved to larger facilities, completed clinical trials and more. Read on to learn more about these fast-growing startups.

Secure your tickets to the 2024 Houston Innovation Awards next Thursday, November 14, at TMC Helix Park.


Cart.com, a unified commerce and logistics solutions provider for B2C and B2B companies

With the acquisition of Amify, Cart.com has expanded its workforce and grown its suite of services. Photo courtesy of Cart.com

Clinching unicorn status with its 2023 series C raise, Cart.com is on a mission to unify commerce across sales and distribution channels and digital and physical capabilities with its omnichannel enterprise-grade software, services and logistics.

Founded in 2020 with nine acquisitions and $759.2 million raised to date, according to Crunchbase, Cart.com's recent achievements includes acquiring Pacsun’s fulfillment operators, brining a 2 million-square-foot facility online, expanding its executive team, and more.

"In the last 12 months, Cart.com has dramatically grown its fulfillment network’s scale and technological capabilities," writes CEO Omail Tariq in his Houston Innovation Awards application.

"We have been laser-focused on improving quality, performance and efficiency at scale while continuing to aggressively grow our customer base, expand our capabilities to customers in new industries and grow our physical presence to new locations," he continues. "Prioritizing our strategic growth initiatives has been critical in the current macroeconomic environment as profitable growth remains paramount for our team."

In 2021, Cart.com moved its headquarters to Austin, with most of the leadership team remaining in Houston. Two years later, the company announced its HQ return to the Bayou City.

"We've found Houston's business and university communities to be incredibly supportive of our efforts and have found the city to be a place that is both easier and more affordable to bring together our global employee population at more regular intervals," Tariq adds in the app.

Coya Therapeutics, a clinical-stage company developing therapies for neurodegenerative, autoimmune, and metabolic diseases

Houston company with revolutionary neurodegenerative disease treatment shares milestones since IPOCoya Therapeutics rang the closing bell at Nasdaq last week, celebrating six months since its IPO, new data from trials, and additions to its team. Photo via LinkedIn

Revolutionary biotech company Coya Therapeutics Inc. (NASDAQ: COYA) may have closed its IPO in January 2023 for more than $15 million, but the company has made some of its most significant strides in the development of its lead product that prevents the further spreading of neurodegenerative diseases this year.

Known as COYA 302, the product uses a unique dual mechanism that is now being developed for the treatment of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson’s disease and Alzheimer’s disease. The company published its phase 1 proof-of-concept study in the peer-reviewed journal Frontiers in Neurology that showed COYA 302's ability to stop clinical progression in ALS at 24 weeks in combination therapy, which helped earn the company a $5 million in strategic investment from the Alzheimer’s Drug Discovery Foundation to continue to develop the product for a planned Phase 2 trial focused on FTD.

Last year the company also added to its C Suite, naming Dr. Arun Swaminathan as chief business officer and Dr. Fred Grossman as president and chief medical officer.

Coya merged with Nicoya Health Inc. and raised $10 million in its series A in 2020.

NanoTech Materials, a chemical manufacturer that integrates novel heat-control technology with thermal insulation, fireproofing, and cool roof coatings to drastically improve efficiency and safety

Growing Houston startup moves into 43,000-square-foot facility amid 'hypergrowth phase'NanoTech Materials celebrated its move into a new facility — a 43,000-square-foot space in Katy, Texas, this week

Mike Francis, co-founder and CEO of NanoTech Materials, told InnovationMap earlier this year that it was in a "hype growth" phase—and meant it.

NanoTech, known for its proprietary Insulative Ceramic ParticleTM (ICP) that uses nanotechnology to optimize energy efficiency and heat control in the built environment, expanded into a new 43,000-square-foot facility this year and tripled its valuation in the last two years, according to its Innovation Awards application. The company also expanded into the Middle East and Singapore and successfully scaled up its NanoTech Cool Roof Coat to commercial markets.

The company closed a $5 million seed round in 2020 and an oversubscribed Series A round last year for $13 million. It was the first company selected for the Houston-based Halliburton Labs in 2021 and joined the Rice Alliance Clean Energy Accelerator in 2023.

Square Robot, an advanced robotics company serving the energy industry and beyond by providing submersible robots for storage tank inspections

Square Robot has a team of 15 in Houston. Photo courtesy\u00a0of Square Robot

Submersible robotics company Square Robot launched its Houston office in 2019 and expanded in the Bayou City this past year.

According to the company's Innovation Award application, the company doubled its fleet of autonomous, submersible robots that service the energy industry, deploying to Malaysia, Vietnam, Thailand, Australia, Kuwait and Saudi Arabia. Its robots are specifically used for storage tank inspections and eliminating the need for humans to enter dangerous and toxic environments.

Square Robot moved to a new, customer-facing Houston facility this year and also developed a new innovative technology that's able to gather phased ultrasonic readings on insulated tank shells while the tank is operational.

The company closed a Series A round in 2018 for $6 million.

Syzygy Plasmonics, a company that's decarbonizing chemical production with a light-powered reactor platform that electrifies the production of hydrogen, syngas, and fuel with reliable, low-cost solutions

Houston climatetech startup selected for inaugural global entrepreneur competitionSyzygy Plasmonics is going to be competing in Gastech's new startup competition. Photo courtesy of Syzygy

Known for the world’s first light-powered reactor cell for industrial chemical reactions, Syzygy Plasmonics began taking orders earlier this year for its Rigel reactor cell after meeting initial performance targets. The cell enables a customer to produce up to five tons of low-carbon hydrogen per day.

The groundbreaking technology earned the company regional, national and global attention. Fast Company magazine placed the company on its energy innovation list. It was also named a finalist for Ernst & Young’s Entrepreneur Of The Year 2024 Gulf South Award and was invited to participate in Gastech's global entrepreneur competition.

The company most recently raised $76 million in a Series C round in 2022.

This week's roundup of Houston innovators includes Howard Berman of Coya Therapeutics, Elad Inbar of RobotLAB, and Steve Altumus of Intuitive Machines. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a robotics expert, a space tech leader, and a therapeutics CEO.

Howard Berman, co-founder and CEO of Coya Therapeutics

This week's episode of the Houston Innovators Podcast revisits a conversation with Howard Berman, co-founder and CEO of Coya Therapeutics. Photo courtesy of Coya

It's been a busy summer for Houston-based Coya Therapeutics, a clinical-stage biotech company that's creating revolutionary treatments for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS.

In July, Coya announced that has expanded its collaboration with Houston Methodist Research Institute, or HMRI. The publicly traded company also announced fresh funding from the Johnson Center for Cellular Therapeutics.

Last month, Coya reported that it has expanded its treatment research to see how GLP-1 drugs — a trending drug for weight loss — can enhance the effects of its proprietary therapeutics. By combining the medicines, Howard Berman, co-founder and CEO of Coya Therapeutics, says he thinks Coya can better treat these complex immune-based diseases. Read more.

Elad Inbar, founder and CEO of RobotLAB

Elad Inbar is the founder and CEO of RobotLAB. Photo courtesy of RobotLAB

Elad Inbar, founder and CEO of RobotLAB, who in July expanded his company’s Texas franchise operations with the opening of a Houston branch.

“For many years, robots were toys — for geeks. You had to build them yourself, program them yourself,” Inbar says.

But the electronics revolution that brought handheld phones to the mainstream inspired Inbar to turn that concept to robotics when he formed RobotLAB in 2007.

“To me, this was completely a wake up call — seeing the market shift, and you know, bringing the opportunity to the mass market,” he says. Read more.

Steve Altemus, co-founder, president, and CEO of Intuitive Machines

Per the contract, Intuitive Machines will provide near space communications and navigation services for NASA. Photo via intuitivemachines.com

Houston-based space exploration, infrastructure, and services company Intuitive Machines has snagged a deal with NASA that could be worth more than $4 billion.

Under the contract, Intuitive Machines (Nasdaq: LUNR, LUNRW) will supply communication and navigation services for missions in the “near space” region, which extends from the earth’s surface to beyond the moon.

The five-year deal includes an option to add five years to the contract. In total, the contract could be worth $4.82 billion. The initial round of NASA funding runs from October 2024 through September 2029.

“This contract marks an inflection point in Intuitive Machines’ leadership in space communications and navigation,” Steve Altemus, CEO of Intuitive Machines, says. Read more.

This week's episode of the Houston Innovators Podcast revisits a conversation with Howard Berman, co-founder and CEO of Coya Therapeutics. Photo courtesy of Coya

Play it back: Houston therapeutics co. sees momentum with expanded treatment opportunities

houston innovators podcast Episode 253

It's been a busy summer for Houston-based Coya Therapeutics, a clinical-stage biotech company that's creating revolutionary treatments for neurodegenerative diseases like Alzheimer’s, Parkinson’s, and ALS.

In July, Coya announced that has expanded its collaboration with Houston Methodist Research Institute, or HMRI. The publicly traded company also announced fresh funding from the Johnson Center for Cellular Therapeutics.

Last month, Coya reported that it has expanded its treatment research to see how GLP-1 drugs — a trending drug for weight loss — can enhance the effects of its proprietary therapeutics. By combining the medicines, Howard Berman, co-founder and CEO of Coya Therapeutics, says he thinks Coya can better treat these complex immune-based diseases.

Berman joined the Houston Innovators Podcast in April of 2023 to discuss taking Coya public and his passion for the company's mission.

"I was interested in what I could do for my dad," Berman says on the Houston Innovators Podcast, explaining how he took the meeting with Dr. Stanley Appel, who then presented him with some of his research. "By slide five my jaw had hit the ground.

"He had shown that he could stop the progression in one of his early trials of ALS," Berman says.

Berman shares more of the Coya Therapeutics story on the podcast, as well as how he sees Houston's potential as an emerging hub for biotech.

"The next number of years as we develop this therapeutic regimen for ALS, we have the potential to transform Houston into something more than it is currently," he says. "Our success will be the city's success."

This week's roundup of Houston innovators includes Dr. Evan Collins of Houston Methodist, Margarita Kelrikh of Pillsbury, and Howard Berman of Coya Therapeutics. Photos courtesy

3 Houston innovators to know this week

who's who

Editor's note: Every week, I introduce you to a handful of Houston innovators to know recently making headlines with news of innovative technology, investment activity, and more. This week's batch includes a new innovator in residency, a Houston startup lawyer, and a neurodegenerative therapeutics CEO.

Evan Collins, innovator in residency at Houston Methodist

Dr. Evan Collins, an orthopedic surgeon and chief of the Houston Methodist Hand & Upper Extremity Center, was named the hospital's first innovator in residency. Photo via drevancollins.com

Dr. Evan Collins, an orthopedic surgeon and chief of the Houston Methodist Hand & Upper Extremity Center, is the inaugural innovator in residency at Houston Methodist Center for Innovation.

What does an innovator-in-residency do? Collins sat down with InnovationMap to explain. His role, he explains, is to encourage other clinicians to get involved in the innovation process, particularly using digital health care programs.

“When you look at all the technology, especially the digital technology that's being applied [in medicine], and the future of digital technology, whether you define it as AI or other variations, having a clinical perspective to vet a lot of these possible solutions, as opposed to just keeping it on the administrative side of things, has greater value,” he says. Read more.

Margarita Kelrikh, counsel at Pillsbury

Margarita Kelrikh joins the Houston Innovators Podcast to discuss her career, legal tips for startups, and why she's dedicated to the Houston startup community. Photo courtesy

After working at WeWork and its upstart competitor for several years, Margarita Kelrikh realized it was time to move back into a law firm where she could help more early stage Houston startup clients. She recently joined Pillsbury's Houston office as counsel.

"I realized I wanted to work with the people who I worked with in the past, and the only way I could do that is if I went back to a law firm," she says, explaining that working in house means you can only have one client: your employer. "It's about having that variety and being able to work with a wide array of people."

Kelrikh shares some of her go-to startup legal advice on this week's episode of the Houston Innovators Podcast, and she emphasizes how ready and willing she is to serve the Houston startup community. Read more.

Howard Berman, CEO and co-founder of Coya Therapeutics

Coya Therapeutics is looking into how a trendy weight loss drug could complement its Alzheimer’s disease treatment. Photo via LinkedIn

Glucagon-like peptide 1, or GLP-1, agonists are all the rage right now thanks to drugs like Ozempic and Wegovy. Though they’re currently being prescribed for diabetes and weight loss, a Houston company reports that it may have found another use for GLP-1s.

Coya Therapeutics, a publicly traded clinical-stage biotechnology company, has filed intellectual property protection for a combination of its proprietary COYA 301 and GLP-1. Coya’s team believes that combining COYA 301, a low-dose interleukin-2 (IL-2) intended to enhance the anti-inflammatory function of regulatory T cells (Tregs), with GLP-1 could be a game-changer in the fight against Alzheimer’s disease.

According to Coya’s CEO, Howard Berman, “We believe that combination immunotherapy approaches will evolve to play a meaningful role in treating complex immune-based diseases that are driven by a host of pathophysiologic mechanisms.” Read more.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Property Showcase

Houston-founded startup raises $1.2M and moves headquarters to Detroit

moving forward

Houston-founded ChurchSpace, known as the Airbnb for churches, has formed an official partnership with the City of Detroit and will relocate its headquarters.

The announcements come as the company successfully closed a $1.2 million oversubscribed funding round. The round was led by California-based Black Ops Ventures, with participation from Michigan Rise and Dug Song of Minor Capital, who is also the founder of the Song Foundation, another Michigan-based organization.

"This raise is more than a business milestone—it's a testament to what happens when strategy meets faith. In today's climate, raising capital takes grit and resilience—especially without deep networks or traditional access. By God's grace, doors have opened, and our mission is clearer than ever. Now, with capital in hand, we're building boldly toward a future where the Church isn't just surviving—but leading community transformation," Emmanuel Brown, co-founder and CEO of ChurchSpace, said in a statement.

In Detroit, ChurchSpace plans to activate underutilized church campuses as micro-logistics spaces for food distribution and retail partnerships, as well as last-mile delivery centers. To kick off its relocation, ChurchSpace will host a Detroit Pastor Meetup on July 19.

"We welcome ChurchSpace's investment in Detroit and the jobs and innovation it will bring," Detroit Mayor Mike Duggan added in the release. "Our faith community has long been a critical backbone of our neighborhoods. Through ChurchSpace's groundbreaking work, they will continue to be anchors of opportunity and resilience in our city's future."

ChurchSpace was originally founded to convert underutilized church real estate into event, meeting and commercial kitchen space to boost revenue and relieve financial burden while remaining compliant with IRS regulations for non-profits. The company participated in the inaugural cohort of the AWS Impact Accelerator for Black Founders, which included a pre-seed fundraising campaign and a $125,000 equity injection from Amazon in 2022. It was also one of two Houston companies to receive $100,000 as part of the Google for Startups Black Founders Fund that same year.

The company reports that its platform in Texas has generated up to $100,000 annually in new revenue that was reinvested into church ministries, food programs and community initiatives.

"What we built in Houston was more than technology—it was transformation. We expanded our purpose and packaged proven strategies to help churches thrive, transform communities, and even combat food insecurity," Day Edwards, co-founder and president of ChurchSpace, added in the statement. "Now, with prayer and the support of our team and investors, we're bringing that same impact to Detroit—to help churches, communities, and small businesses redefine pulpits and rediscover communal possibilities."

Houston space tech co. lands millions and more innovation news to know

Trending News

Editor's note: It's time to recap the top innovation news for the first half of May 2025. Our five most-read stories from May 1-15 include updates from Intuitive Machines and The Ion. Plus, driverless trucks hit the road from Houston to Dallas. Get all of the details below.

1. Houston space tech leader lands up to $10 million for Earth re-entry vehicle and lab

The Texas Space Commission has selected Houston's Intuitive Machines to develop a vehicle that will return lunar samples to Earth, along with an orbital fabrication lab. Photo courtesy Intuitive Machines.

Houston-based space technology, infrastructure, and services company Intuitive Machines has been awarded a state grant of up to $10 million to help develop an Earth re-entry vehicle and in-space biomanufacturing lab. The Texas Space Commission approved the grant, which is coming from the state’s Space Exploration and Research Fund. Intuitive Machines says the money will support its “critical risk-reduction platform” for returning lunar samples to Earth. The funding will go toward an early 12-month phase of the project. Continue reading.

2. 9 can't-miss Houston business and innovation events for May

Don't miss these May events — from an investor activation series to a crawfish cook-off. Photo courtesy Greentown Labs.

There's a lot to learn this month at events around Houston. Hear from AI and energy experts or gain insights into how to tap into funding at informative panels or sessions. Continue reading.

3. Autonomous truck company rolls out driverless Houston-Dallas route

Aurora began regular driverless deliveries between Houston and Dallas on April 27. Photo courtesy Aurora.

Houston is helping drive the evolution of self-driving freight trucks. In October, Aurora opened a more than 90,000-square-foot terminal at a Fallbrook Drive logistics hub in northwest Houston to support the launch of its first “lane” for driverless trucks—a Houston-to-Dallas route on the Interstate 45 corridor. Aurora opened its Dallas-area terminal in April and the company began regular driverless customer deliveries between the two Texas cities on April 27. Continue reading.

4. Texas-based 'DoorDash for laundry' startup tumbles into Houston market

The service has been a smash success in Austin. Courtesy photo

Laundry may seem like an endless task that piles up, but a new service offers a solution to overwhelmed Houston families. NoScrubs, an Austin-based home laundry pickup service has just expanded to Houston. Described by the company as "DoorDash — but for laundry," they wash customer's clothes at local laundromats and return them the same day, folded and ready to be put away. The service took off like gangbusters in Austin, making an expansion to the state's largest city an obvious choice. Continue reading.

5. New energy innovation and coworking spaces open at the Ion

The Oxy Innovation Center has opened at the Ion and Industrious' coworking space launches soon. Photo courtesy of The Ion

Houston-based Occidental officially opened its new Oxy Innovation Center with a ribbon cutting at the Ion. The opening reflects Oxy and the Ion's "shared commitment to advancing technology and accelerating a lower-carbon future," according to an announcement from the Ion. Oxy, which was named a corporate partner of the Ion in 2023, now has nearly 6,500 square feet on the fourth floor of the Ion. Rice University and the Rice Real Estate Company announced the lease of the additional space last year, along with agreements with Fathom Fund and Activate. Continue reading.

Houston healthtech leader launches clinical trial for innovative anxiety-treating device

making waves

Houston-based Nexalin Technology’s proprietary neurostimulation device will move forward with a new clinical trial evaluating its treatment of anxiety disorders and chronic insomnia in Brazil.

The first of Nexalin’s Gen-2 15-milliamp neurostimulation devices have been shipped to São Paulo, Brazil, and the study will be conducted at the Instituto de Psiquiatria university hospital (IPq-HCFMUSP). The shipments aim to support the launch of a Phase II clinical trial in adult patients suffering from anxiety and insomnia, according to a news release.

“Brazil is an important emerging market for mental health innovation, and this collaboration marks our first IRB-approved study in the region,” Mike White, CEO of Nexalin, said in the release.

The study will be led by Dr. Andre Russowsky Brunoni, who specializes in neuromodulation and interventional psychiatry. He currently serves as director of the interventional psychiatry division at IPq-HCFMUSP and this summer will join UT Southwestern in Dallas and its Peter O’Donnell Jr. Brain Institute as a professor of psychiatry.

The Phase II study plans to enroll 30 adults in São Paulo and assess the efficacy of Nexalin’s non-invasive deep intracranial frequency stimulation (DIFS™) of the brain in reducing anxiety symptoms and improving sleep quality, according to the company. Using the Hamilton Anxiety Rating Scale (HAM-A), the trial’s goal is a reduction in anxiety symptoms, and assessments of sleep onset latency, total sleep time, overall sleep quality, depressive symptoms and clinical impression of improvement. The company plans to share results in a peer-reviewed scientific journal.

“Anxiety and insomnia are very common conditions that often occur together and cause significant distress,” Brunoni added in the news release. “In this study, we are testing a new, non-invasive brain stimulation technology that has shown promising results in recent research. Our goal is to offer a safe, painless, and accessible alternative to improve people’s well being and sleep quality.”

The Nexalin Gen-2 15-milliamp neurostimulation device has been approved in China, Brazil, and Oman.

The company also enrolled the first patients in its clinical trial at the University of California, San Diego, in collaboration with the VA San Diego Healthcare System for its Nexalin HALO, which looks to treat mild traumatic brain injury and post-traumatic stress disorder in military personnel and the civilian population. It also recently raised $5 million through a public stock offering. Read more here.

View All Listings